PCM
OBIO icon

Prelude Capital Management’s Orchestra BioMed OBIO Stock Holding History

Prelude Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.7K Buy
+12,389
New +$52.7K ﹤0.01% 1124

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Prelude Capital Management's OBIO Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Orchestra BioMed (OBIO) in Q1 2026: 12,389 shares worth $52.7K. The stake represents ﹤0.01% of the portfolio and ranks #1124 among its holdings.

65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Prelude Capital Management held 12,389 shares of Orchestra BioMed worth $52.7K as of Q1 2026.
  • Orchestra BioMed was a new Prelude Capital Management position in Q1 2026.
  • Orchestra BioMed made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1124 holding.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.